A Russian drug for blood clots has entered the final phase of clinical trials. Scientists have developed the drug "Angifor", which belongs to antiplatelet drugs - drugs that prevent platelets from sticking together and forming blood clots. Work on the drug has been going on for ten years, RIA Novosti reported. The drug is designed to be used for myocardial infarction, as well as for the installation of stents to restore blood flow in the coronary arteries. Anjapur should become an alternative to imported drugs, the supply of which is difficult. Its production will not depend on consumables and foreign equipment.

A Russian drug for blood clots has entered the final phase of clinical trials. Scientists have developed the drug "Angifor", which belongs to antiplatelet drugs - drugs that prevent platelets from sticking together and forming blood clots. Work on the drug has been going on for ten years, RIA Novosti reported. The drug is designed to be used for myocardial infarction, as well as for the installation of stents to restore blood flow in the coronary arteries. Anjapur should become an alternative to imported drugs, the supply of which is difficult. Its production will not depend on consumables and foreign equipment.